Nils Lycke Selected Research

Vaccines

1/2022	Clonotypic analysis of protective influenza M2e-specific lung resident Th17 memory cells reveals extensive functional diversity.
1/2021	A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection.
5/2020	Prevention of influenza virus infection and transmission by intranasal administration of a porous maltodextrin nanoparticle-formulated vaccine.
12/2019	Type I and Type III Interferons Differ in Their Adjuvant Activities for Influenza Vaccines.
1/2018	Porous Nanoparticles With Self-Adjuvanting M2e-Fusion Protein and Recombinant Hemagglutinin Provide Strong and Broadly Protective Immunity Against Influenza Virus Infections.
1/2018	ADP-ribosylating enterotoxins as vaccine adjuvants.
12/2016	Protection against genital tract Chlamydia trachomatis infection following intranasal immunization with a novel recombinant MOMP VS2/4 antigen.
7/2012	Recent progress in mucosal vaccine development: potential and limitations.
2/2008	CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
11/2006	Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nils Lycke Research Topics

Disease

16	Infections 01/2022 - 12/2002
8	Human Influenza (Influenza) 01/2021 - 11/2006
4	Inflammation (Inflammations) 01/2015 - 12/2002
2	Virus Diseases (Viral Diseases) 01/2022 - 12/2019
2	Gastritis 04/2004 - 12/2002
1	Caliciviridae Infections 11/2020
1	Communicable Diseases (Infectious Diseases) 12/2019
1	Synovitis 01/2015
1	Arthritis (Polyarthritis) 01/2015
1	Infectious Arthritis (Septic Arthritis) 01/2015
1	Poliomyelitis (Polio) 07/2012
1	Rotavirus Infections 07/2012
1	Experimental Arthritis 06/2009
1	Reproductive Tract Infections 09/2007
1	Reinfection 09/2007
1	Eosinophilia 09/2004

Drug/Important Bio-Agent (IBA)

11	VaccinesIBA 01/2022 - 09/2004
6	AntigensIBA 01/2021 - 02/2008
4	Influenza Vaccines (Influenza Vaccine)FDA Link 05/2020 - 01/2006
3	Cholera ToxinIBA 01/2021 - 06/2009
3	Immunoglobulin A (IgA)IBA 12/2019 - 01/2018
3	AntibodiesIBA 12/2019 - 04/2004
3	Proteins (Proteins, Gene)FDA Link 01/2018 - 02/2008
2	Subunit VaccinesIBA 01/2021 - 12/2019
2	CytokinesIBA 06/2009 - 09/2004
2	Interleukin-12 (IL 12)IBA 09/2004 - 12/2002
1	Adenosine Diphosphate (ADP)IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Thymic Stromal LymphopoietinIBA 01/2021
1	InterferonsIBA 01/2021
1	Lipid NanoparticlesIBA 01/2021
1	GlycosphingolipidsIBA 11/2020
1	Blood Group Antigens (Blood Groups)IBA 11/2020
1	CarbohydratesIBA 11/2020
1	Viral AntigensIBA 05/2020
1	maltodextrinIBA 05/2020
1	Polysaccharides (Glycans)IBA 05/2020
1	Interferon LambdaIBA 12/2019
1	Combined VaccinesIBA 01/2018
1	Hemagglutinins (Hemagglutinin)IBA 01/2018
1	Receptor for Advanced Glycation End ProductsIBA 01/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2015
1	Cloxacillin (Tegopen)FDA Link 01/2015
1	Bacterial DNAIBA 01/2015
1	Type I Tumor Necrosis Factor ReceptorsIBA 01/2015
1	Toll-Like Receptor 2IBA 01/2015
1	CTA1R7K-COL-DDIBA 06/2009
1	Collagen Type II (Type II Collagen)IBA 06/2009
1	Peptides (Polypeptides)IBA 06/2009
1	EpitopesIBA 02/2008
1	Messenger RNA (mRNA)IBA 09/2007
1	Interferon-gamma (Interferon, gamma)IBA 09/2007
1	Interleukin-10 (Interleukin 10)IBA 09/2007
1	Amino Acids FDA Link 11/2006
1	Membrane Proteins (Integral Membrane Proteins)IBA 11/2006
1	Interleukin-18 (Interleukin 18)IBA 09/2004

Therapy/Procedure

2	Intranasal Administration 05/2020 - 01/2006
1	Injections 01/2018
1	Intra-Articular Injections 01/2015
1	Therapeutics 01/2015